Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
A fantastic opportunity to showcase your transformative work within the region in a truly international platform.
A comprehensive update in medical oncology and an excellent way to prepare for the ESMO Examination with leading global experts!
Extended deadline until 29 April 2025
Present your new data at this multidisciplinary congress where leading experts will review innovations in genito-urinary cancers care
Access the resources for this in-depth discussion with the specialists in the field to know about hot topics and future trends
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
In a video series produced by the ESMO Women for Oncology, Solange Peters reflects on her career and the leadership challenges she has faced
Findings from an integrated analysis of the pivotal phase II regional TRUST-I and global TRUST-II studies
Evidence for efficacy is based on the results from the CABINET study
Robust life sciences are fundamental for advancing the understanding of cancer, driving therapeutic innovation in oncology, and ultimately delivering new treatments benefitting patients with cancer.
New indication concerns the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified who are ineligible for autologous stem cell transplant
An up-to-date projection of cancer mortality patterns in the European Union
Findings from the SUNNIFORECAST study
Findings from the 3475A-D77 study
Evidence for efficacy is based on the results from the KEYNOTE-811 study
Findings from an integrated analysis of the pivotal phase II regional TRUST-I and global TRUST-II studies
Evidence for efficacy is based on the results from the CABINET study
New indication concerns the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified who are ineligible for autologous stem cell transplant
An up-to-date projection of cancer mortality patterns in the European Union
Findings from the SUNNIFORECAST study
Findings from the 3475A-D77 study
Evidence for efficacy is based on the results from the KEYNOTE-811 study
It is intended for the treatment of patients with relapsed and refractory multiple myeloma
Findings from the KEYNOTE-921 study
The European Lung Cancer Congress 2025 is the event dedicated to the prevention, diagnosis, and management of thoracic malignancies
The ESMO Sarcoma and Rare Cancers Congress 2025, to be held from 20-22 March in Lugano, Switzerland, will be the convergence point for world-renowned experts to present and discuss developments in the diagnosis and treatment of rare solid tumours, going through their peculiar biology and molecular classification, while also addressing the methodological, organisational, and policy challenges that characterise this oncological area and its high unmet needs
Experts predict death rates from all cancers for the EU and UK for 2025
The ESMO Targeted Anticancer Therapies Congress 2025 will showcase state-of-the-art and the latest advancements in new drug development, with focus on new targets, tumour-agnostic drug development, the role of artificial intelligence in drug development, radiotheranostics and cell therapies for solid tumours
The ESMO Immuno-Oncology Congress 2024 will take place in Geneva, Switzerland, from December 11-13, with an option to attend virtually. Leading experts will present and discuss the research advancements in the rapidly evolving field of immuno-oncology
The ESMO Asia Congress 2024 is the annual event dedicated to multidisciplinary oncology in the Asian region
The Molecular Analysis for Precision Oncology Congress 2024 (MAP) is the appointment where globally recognised experts will present and discuss research in precision medicine, technologies for cancer profiling, mechanisms driving tumour expansion, metastatic dissemination, clonal evolution, and biomarker-driven development of targeted therapeutics
Immunotherapy, which works by enabling the body’s immune system to recognise and destroy cancer cells improves long-term overall survival in patients with advanced melanoma in results from large international studies reported at ESMO 2024
Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a first-in-human study found ‘promising’ antitumour activity with a novel antibody drug conjugate (ADC) targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers
It is with great sadness that ESMO has learnt of the passing of Maurice Schneider, one of the Society’s co-founders
At a time when innovation is more critical than ever in oncology, ESMO is determined to ensure that regulatory developments support, rather than hinder, cancer research in Europe
The European Society for Medical Oncology (ESMO) announced today that the recipient of the 2025 ESMO Breast Cancer Award is Gabriel N. Hortobagyi, Professor of Medicine in the Department of Breast Medical Oncology at The University of Texas M.D. Anderson Cancer Center, USA
The European Society for Medical Oncology (ESMO) announced today that the recipient of the 2025 Heine H. Hansen Award is Keith Kerr, Consultant Pathologist for NHS Grampian and Honorary Chair in Pulmonary Pathology at the University of Aberdeen in Scotland
Burnout is an increasingly pressing concern for the oncology community
This year marks the 10th anniversary of the ESMO Women for Oncology (W4O) Committee, a decade-long commitment to advancing gender equity in oncology
ESMO reaffirms its commitment to working with EU stakeholders to maximize the potential of the Beating Cancer Plan
Bringing together cancer patient advocates from around the world will create a bridge between diverse experiences and perspectives and help secure the optimisation of patient care worldwide
The nomination process for the 2025 ESMO Society Awards is now open
In a video series produced by the ESMO Women for Oncology, Solange Peters reflects on her career and the leadership challenges she has faced
While many models and tools are designed to support clinical decision-making, AI is already serving cancer research for background tasks, with some potential to educate patients too
Newly released recommendations address key areas to facilitate the integration of precision oncology in clinical practice
An improvement was observed when immunotherapy was added to neoadjuvant chemotherapy, but further data are needed to confirm the survival benefit
Final results from the MARIPOSA trial provide further supporting evidence to the first-line treatment combination
While strategies for drug de-escalation continue to be actively pursued, some challenges including insufficient funding of research still limit their applicability
Results from the ETOP AMAZE-lung and COCOON trials show some promise to improve safety and reduce skin adverse events
Phase III data in metastatic NSCLC support an alternative route of administering immunotherapy, which may have an impact on patients’ preferences and cancer care costs
Studies evaluate the efficacy and safety of promising agents including adagrasib and fulzerasib
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Germany
Netherlands
Austria
Spain
Hong Kong SAR, China
Czech Republic
France
Germany
Germany
Czech Republic
Republic of Singapore
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Examination 2025 will be held on Saturday 18 October during the ESMO Congress 2025.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
